Table 2.
Patterns of immunosuppressive regimens among heart transplant recipients at ambulatory visits, 2000–2009
| Year | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total regimens | 10 | 15 | 15 | 16 | 15 | 16 | 15 | 15 | 17 | 28 |
| Total prescriptions | 176 | 737 | 969 | 1207 | 1769 | 2390 | 2974 | 3362 | 3875 | 4345 |
| Single-drug regimens (%) | 4.54 | 11.80 | 20.02 | 17.90 | 18.15 | 12.38 | 13.72 | 17.19 | 14.66 | 10.52 |
| STE | 2.27 | 4.07 | 2.58 | 2.49 | 2.60 | 1.30 | 0.77 | 1.22 | 1.44 | 1.43 |
| CSA | 0.57 | 1.63 | 3.30 | 5.72 | 7.01 | 7.45 | 8.44 | 10.95 | 9.42 | 5.96 |
| TAC | 0 | 1.36 | 1.34 | 2.07 | 2.60 | 3.26 | 3.90 | 4.46 | 3.74 | 2.72 |
| MPA | 1.70 | 4.75 | 12.59 | 7.13 | 5.31 | 0.33 | 0.61 | 0.57 | 0.36 | 0.30 |
| AZA | 0 | 0 | 0.21 | 0.50 | 0.62 | 0.04 | 0 | 0 | 0 | 0 |
| EVL | 0 | 0.12 | ||||||||
| Two-drug regimens (%) | 23.87 | 27.14 | 29.82 | 31.07 | 29.34 | 48.95 | 50.37 | 48.33 | 47.79 | 43.33 |
| CSA-based | ||||||||||
| +STE | 9.66 | 6.24 | 4.33 | 4.31 | 4.52 | 12.38 | 16.91 | 14.19 | 16.08 | 11.05 |
| +MPA | 1.14 | 8.01 | 17.44 | 15.91 | 17.58 | 22.85 | 18.43 | 16.75 | 12.41 | 10.13 |
| +AZA | 0 | 1.22 | 1.24 | 2.15 | 0.96 | 0.88 | 0.67 | 0.51 | 0.62 | 0.55 |
| +EVL | 0 | 3.38 | ||||||||
| TAC-based | ||||||||||
| +STE | 2.84 | 2.58 | 0.21 | 1.08 | 0.57 | 4.77 | 3.80 | 3.54 | 4.70 | 5.39 |
| +MPA | 0 | 0.14 | 0.31 | 0.41 | 0.90 | 7.41 | 8.37 | 10.71 | 10.97 | 9.14 |
| +AZA | 0 | 0 | 0 | 0 | 0.11 | 0.54 | 1.88 | 2.56 | 2.35 | 1.17 |
| +EVL | 0 | 1.84 | ||||||||
| Others | ||||||||||
| MPA + STE | 10.23 | 3.66 | 4.54 | 5.47 | 4.69 | 0.13 | 0.30 | 0.09 | 0.57 | 0.53 |
| AZA + STE | 0 | 5.29 | 1.75 | 1.74 | 0 | 0 | 0 | 0 | 0.10 | 0.02 |
| MPA + EVL | 0 | 0.09 | ||||||||
| EVL + STE | 0 | 0.05 | ||||||||
| Three-drug regimens (%) | 71.59 | 61.06 | 50.15 | 51.04 | 52.52 | 38.66 | 35.91 | 34.47 | 37.55 | 44.65 |
| CSA-based | ||||||||||
| +MPA + STE | 40.91 | 39.08 | 37.15 | 44.57 | 45.34 | 22.72 | 21.69 | 20.14 | 22.53 | 22.62 |
| +AZA + STE | 21.59 | 14.79 | 8.05 | 2.07 | 0.68 | 0.79 | 0.13 | 0.45 | 0.23 | 0.32 |
| +MPA + EVL | 0 | 0.14 | ||||||||
| +EVL + STE | 0.13 | 3.94 | ||||||||
| TAC-based | ||||||||||
| +MPA + STE | 9.09 | 6.11 | 4.95 | 4.31 | 6.50 | 14.73 | 13.99 | 13.41 | 14.30 | 14.96 |
| +AZA + STE | 0 | 1.09 | 0 | 0.08 | 0 | 0.42 | 0.10 | 0.48 | 0.36 | 0.18 |
| +MPA + EVL | 0 | 0.64 | ||||||||
| +EVL + STE | 0 | 1.80 | ||||||||
| Others | ||||||||||
| MPA + STE + EVL | 0 | 0.05 | ||||||||
| Four-drug regimens (%) | 1.50 | |||||||||
| CSA + MPA + EVL + STE | 0 | 0.99 | ||||||||
| TAC + MPA + EVL + STE | 0 | 0.51 | ||||||||
AZA, azathioprine; CSA, cyclosporine; EVL, everolimus; MPA, mycophenolic acid; STE, corticosteroids; TAC, tacrolimus.